ATE207750T1 - Verwendung vom 3-alpha-hydroxy-5alpha-androsta-16-ene als arzneimittel - Google Patents

Verwendung vom 3-alpha-hydroxy-5alpha-androsta-16-ene als arzneimittel

Info

Publication number
ATE207750T1
ATE207750T1 AT96402710T AT96402710T ATE207750T1 AT E207750 T1 ATE207750 T1 AT E207750T1 AT 96402710 T AT96402710 T AT 96402710T AT 96402710 T AT96402710 T AT 96402710T AT E207750 T1 ATE207750 T1 AT E207750T1
Authority
AT
Austria
Prior art keywords
alpha
androsta
ene
hydroxy
5alpha
Prior art date
Application number
AT96402710T
Other languages
English (en)
Inventor
Daniel Philibert
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE207750T1 publication Critical patent/ATE207750T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT96402710T 1995-12-13 1996-12-12 Verwendung vom 3-alpha-hydroxy-5alpha-androsta-16-ene als arzneimittel ATE207750T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9514750A FR2742337B1 (fr) 1995-12-13 1995-12-13 Application du 3-alpha-hydroxy-5-alpha-androsta-16-ene a titre de medicaments

Publications (1)

Publication Number Publication Date
ATE207750T1 true ATE207750T1 (de) 2001-11-15

Family

ID=9485442

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96402710T ATE207750T1 (de) 1995-12-13 1996-12-12 Verwendung vom 3-alpha-hydroxy-5alpha-androsta-16-ene als arzneimittel

Country Status (9)

Country Link
US (1) US5696107A (de)
EP (1) EP0779075B1 (de)
JP (1) JPH09176183A (de)
AT (1) ATE207750T1 (de)
DE (1) DE69616484T2 (de)
DK (1) DK0779075T3 (de)
ES (1) ES2162992T3 (de)
FR (1) FR2742337B1 (de)
PT (1) PT779075E (de)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR676202A (fr) * 1928-06-06 1930-02-20 Serrure à pène applicable aux portes fermant à gauche et à droite
US5155045A (en) * 1985-01-25 1992-10-13 Trustees Of The University Of Penn. Use of male essence to alter female endocrine response
EP0209590A1 (de) * 1985-01-25 1987-01-28 Monell Chemical Senses Center Verwendung männlicher essenz, enthaltende androstenol und dehydroepiandrosteronsulfat bei der behandlung von lutealphasenstörungen und ovulationsabwesenheit bei frauen
JPH01115892A (ja) * 1987-10-29 1989-05-09 Mitsubishi Electric Corp 液相成長装置
US5272134A (en) * 1992-03-24 1993-12-21 Erox Corporation Fragrance compositions and other compositions which contain human pheromones
FR2717690B1 (fr) * 1994-03-24 1996-04-26 Roussel Uclaf Application de stéroïdes aromatiques 3 substitués par un aminoalcoxy substitué à l'obtention d'un médicament pour contrôler la stérilité, notamment masculine.
WO1996036230A1 (en) * 1995-05-16 1996-11-21 The Salk Institute For Biological Studies Modulators for new members of the steroid/thyroid superfamily of receptors

Also Published As

Publication number Publication date
US5696107A (en) 1997-12-09
EP0779075A1 (de) 1997-06-18
JPH09176183A (ja) 1997-07-08
DE69616484D1 (de) 2001-12-06
ES2162992T3 (es) 2002-01-16
FR2742337A1 (fr) 1997-06-20
PT779075E (pt) 2002-04-29
FR2742337B1 (fr) 1998-03-06
EP0779075B1 (de) 2001-10-31
DK0779075T3 (da) 2002-02-18
DE69616484T2 (de) 2002-04-04

Similar Documents

Publication Publication Date Title
ATE494009T1 (de) Prodrugs, ihre herstellung und verwendung als arzneimittel
DE69627042D1 (de) Isocumarinderivate und deren verwendung in medikamenten
ATE199250T1 (de) Sulfonamidocarbonylpyridin-2-carbonsäureamide und ihre verwendung als arzneimittel
ATE248594T1 (de) Irbesartanhaltiges arzneimittel
ATE94869T1 (de) Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika.
ATE175669T1 (de) Sulfonylaminopyrimidine, ihre herstellung und verwendung als heilmittel
AU3462993A (en) Remedy for dermatopathy and metallothionein inducer
DE69429821D1 (de) Farnesyl-derivate und diese enthaltende arzneimittel
DE69333072D1 (de) Topisch anzuwendendes arzneimittel enthaltend hyaluronsäure und nsaids
ES2102475T3 (es) Nuevas alquil-amidas heterociclicas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ATE121295T1 (de) Augentropfenarzneimittel.
EP0823255A4 (de) Sucralfat enthaltendes arzneimittel
DE59407431D1 (de) Verwendung aromatischer Carbonsäurederivate zur Herstellung von pharmazeutischen Präparaten
EP0683668A4 (de) Präparate und verfahren für eine transdermale arzneistoffverabreichung.
DE59611111D1 (de) Phospholipid-derivate von phosphonocarbonsäuren, deren herstellung sowie deren verwendung als antivirale arzneimittel
IT1282778B1 (it) Vitamina "e" acetato quale prodotto per applicazione topica
AU4751293A (en) Compostable disposable personal care articles
ATE183088T1 (de) Arzneimittel zur behandlung von hauterkrankungen
ATE207750T1 (de) Verwendung vom 3-alpha-hydroxy-5alpha-androsta-16-ene als arzneimittel
CA2075926A1 (en) Hydroquinone amino-acid esters, method of preparation, and pharmaceutical or cosmetic compositions containing them
DE69404974D1 (de) (s)-alpha-phenyl-2-pyridinethanamin(s)-malat und seine verwendung als arzneimittel
ATE119394T1 (de) Verwendung von myricetin-3-0-beta-d-glucuronid als arzneimittel.
ATE157360T1 (de) Thienocyclopentanonoximether, ihre herstellung und diese enthaltende arzneimittel
DE59003446D1 (de) 13-Brom und 13, 14-Dibrom-Ergoline, ihre Herstellung und Verwendung in Arzneimitteln.
DE68906437D1 (de) L-pyroglutamyl-l-cystein-dipeptid mit hoher anti-cataractogener wirkung und dies enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee